Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BiomX ( (PHGE) ) has issued an announcement.
On November 25, 2025, BiomX Inc. announced updates regarding its Phase 2b study of BX004 for Cystic Fibrosis treatment, which faced a clinical hold by the FDA due to concerns over a third-party nebulizer device. The company is actively working with the manufacturer to resolve these issues and anticipates resuming U.S. enrollment once resolved and financing is secured. Additionally, an independent Data Monitoring Committee recommended continuing the study with an adjusted dosing regimen after a safety review, with topline results expected in the second quarter of 2026, contingent on financial resources.
The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
BiomX’s overall score is driven by significant financial challenges, including negative revenues and high leverage, which are key risks. However, recent positive trial results and funding announcements provide potential for future growth and improvement.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
BiomX Inc. operates in the biotechnology industry, focusing on developing innovative treatments for various diseases. The company’s primary product in focus is BX004, a drug candidate aimed at treating Cystic Fibrosis, with a market focus on addressing unmet medical needs in this area.
Average Trading Volume: 811,315
Technical Sentiment Signal: Sell
Current Market Cap: $8.37M
Find detailed analytics on PHGE stock on TipRanks’ Stock Analysis page.